Description
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of Patients with Stage I/II Non Small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Location: SIMR (Sacramento/Valley Area)
Please contact: Isabel Rodrigues-Fong (RodrigI@sutterhealth.org) or Kirsten Babski (BabskiK@sutterhealth.org)
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Vijay Suhag, M.D., Anthony T Pu, Radiation Oncologist, Charlotte D Kubicky, Radiation Oncologist, Hubert Y Pan, Radiation Oncologist, Sivakumar Reddy, M.D., Deepti Behl, MD, Carlin R Hauck, Radiation Oncologist
Recruitment Status
Active, Recruiting
Funder
Astra Zeneca
Start Date
October 22, 2020
Related Studies
SEER Lung Cancer
Investigator: Tze-Ming Chen, M.D., FCCP
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH